1st gene therapy for severe hemophilia A approved

BioMarin Pharmaceutical attained the first FDA approval for a gene therapy indicated to treat severe hemophilia A. 

Roctavian (valoctocogene roxaparvovec-rvox) was approved June 29 to reduce bleeding in adults patients with the blood disorder, according to a news release from the San Rafael, Calif.-based drugmaker. 

Every year, hemophilia A affects 1 in 5,000 male births, according to the CDC. Because of the rarity of the disorder, the approval was based on a study of about 130 patients. In the trial, the drug reduced annualized bleeding rate in hemophilia A patients, on average, by 52 percent.

The drug's cost is $2.9 million.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars